Stock Movers Fresnillo Gains, AstraZeneca Rebounds, Nexans Drops
Oct 13, 2025
Fresnillo is riding high as HSBC upgrades its stock amid record gold and silver prices. AstraZeneca rebounds with a strategic deal to lower US drug prices, trading tariff relief for cost cuts. Meanwhile, Nexans faces a steep decline after unexpected CEO changes raise concerns about future growth. The market dynamics are buzzing!
AI Snips
Chapters
Transcript
Episode notes
Precious Metals Rally Lifts Fresnillo
- Fresnillo's shares rallied as gold and silver hit multi-decade highs, benefiting miners directly.
- The company is up over 300% year-to-date amid safe-haven demand and trade tensions.
AstraZeneca's US Pricing Deal And Impacts
- AstraZeneca agreed to cut some US drug prices in exchange for tariff relief and will launch new medicines at the lowest prices offered elsewhere.
- The deal includes deep discounts for Medicaid and sales through a direct-to-consumer Trump Rx platform planned for 2026.
Pharma Deals May Become The New Norm
- AstraZeneca's moves follow earlier commitments like large U.S. manufacturing investments to appease policymakers.
- This sets a precedent likely to pressure other drugmakers to strike similar deals with the administration.